| Original language | English (US) |
|---|---|
| Pages (from-to) | 597-607 |
| Number of pages | 11 |
| Journal | Heart Failure Clinics |
| Volume | 18 |
| Issue number | 4 |
| DOIs | |
| State | Published - Oct 2022 |
Keywords
- Atherosclerosis
- Myocardial infarction
- Sodium-glucose cotransporter-2 inhibitors
- Stroke
- Type 2 diabetes mellitus
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Heart Failure Clinics, Vol. 18, No. 4, 10.2022, p. 597-607.
Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Sodium-Glucose Cotransporter-2 Inhibitors
T2 - Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events
AU - Nelson, Adam J.
AU - Harrington, Josephine L.
AU - Kolkailah, Ahmed A.
AU - Pagidipati, Neha J.
AU - McGuire, Darren K.
N1 - Funding Information: A.J. Nelson—nothing to disclose; Josephine Harrington—completed work for this article while grant (T32HL069749); A.A. Kolkailah—was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number T32HL12547. The content is solely the responsibility of the authors and does not necessarily represent the official view of the National Institutes of Health; N.J. Pagidipati - Grants from Amgen, Novartis, Novo Nordisk, Boehringer Ingelheim, Eli Lilly & Co, Cleerly, Eggland's Best, and Verily Life Sciences; personal fees from Boehringer Ingelheim, Eli Lilly & Co, Novo Nordisk, Novartis; D.K. McGuire - Personal fees from Boehringer Ingelheim, Sanofi US, Merck. Merck Sharp and Dohme. Eli Lilly & Co USA, Novo Nordisk, AstraZeneca, Lexicon Pharmaceuticals, Eisai, Pfizer, Metavant, Applied Therapeutics, Afimmune, Bayer, CSL Behring and Esperion. Funding Information: A.J. Nelson—nothing to disclose; Josephine Harrington—completed work for this article while grant (T32HL069749); A.A. Kolkailah—was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number T32HL12547 . The content is solely the responsibility of the authors and does not necessarily represent the official view of the National Institutes of Health; N.J. Pagidipati - Grants from Amgen , Novartis , Novo Nordisk , Boehringer Ingelheim , Eli Lilly & Co , Cleerly , Eggland’s Best , and Verily Life Sciences ; personal fees from Boehringer Ingelheim , Eli Lilly & Co , Novo Nordisk , Novartis ; D.K. McGuire - Personal fees from Boehringer Ingelheim , Sanofi US , Merck ., Merck Sharp and Dohme ., Eli Lilly & Co USA , Novo Nordisk , AstraZeneca , Lexicon Pharmaceuticals , Eisai , Pfizer , Metavant , Applied Therapeutics , Afimmune , Bayer , CSL Behring and Esperion .
PY - 2022/10
Y1 - 2022/10
KW - Atherosclerosis
KW - Myocardial infarction
KW - Sodium-glucose cotransporter-2 inhibitors
KW - Stroke
KW - Type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=85139420790&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139420790&partnerID=8YFLogxK
U2 - 10.1016/j.hfc.2022.03.007
DO - 10.1016/j.hfc.2022.03.007
M3 - Review article
C2 - 36216489
AN - SCOPUS:85139420790
SN - 1551-7136
VL - 18
SP - 597
EP - 607
JO - Heart Failure Clinics
JF - Heart Failure Clinics
IS - 4
ER -